2,2,4,4,6,6-Hexamethyl-S-trithiane - CAS 828-26-2
Catalog number: 828-26-2
Category: Main Product
Molecular Formula:
C9H18S3
Molecular Weight:
222.43
COA:
Inquire
Purity:
95%
Appearance:
clear colorless to light yellow liquid
Synonyms:
2,2,4,4,6,6-hexamethyl-s-trithian; 2,2,4,4,6,6-Hexamethyl-s-trithiane (trithioacetone); 5-trithiane,2,2,4,4,6,6-hexamethyl-3; Hexamethyl-1,3,5-trithiane; Hexamethyl-s-trithiane; s-Trithiane, 2,2,4,4,6,6-hexamethyl-; TRITHIOACETONE; FEMA 3475
Storage:
Flammables area
MSDS:
Inquire
Boiling Point:
52ºC
Melting Point:
24ºC
Density:
1.065
Physical Description:
2,2,4,4,6,6-Hexamethyl-S-trithiane (25g)
1.The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty.
Piirainen A1,2, Kokki M3,4, Hautajärvi H5, Lehtonen M6, Miettinen H7, Pulkki K8, Ranta VP6, Kokki H1,2. Clin Drug Investig. 2016 Apr 16. [Epub ahead of print]
BACKGROUND AND OBJECTIVE: Based on earlier literature, etoricoxib may have a delayed analgesic effect in postoperative setting when analgesic efficacy of nonselective nonsteroidal anti-inflammatory drug dexketoprofen is rapid. This may be caused by slow penetration of etoricoxib into the central nervous system (CNS). Therefore we decided to determine the plasma and cerebrospinal fluid (CSF) pharmacokinetics and pharmacodynamics of dexketoprofen and etoricoxib in patients with hip arthroplasty.
2.Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.
Beesley VL1, Wockner LF2, O'Rourke P2, Janda M3, Goldstein D4,5, Gooden H6, Merrett ND7,8, O'Connell DL9, Rowlands IJ10, Wyld DK11,12, Neale RE2. Support Care Cancer. 2016 Apr 16. [Epub ahead of print]
PURPOSE: This study aims to determine if the supportive care needs of people with pancreatic cancer change over time and identify the factors associated with current and future unmet needs.
3.Involuntary psychiatric holds - the structure of admissions on the example of Institute of Psychiatry and Neurology in Warsaw.
Markiewicz I1, Heitzman J1, Gardyńska-Ziemba E2. Psychiatr Pol. 2016;50(1):7-18. doi: 10.12740/PP/33336.
OBJECTIVES: The aim of the study was to analyse the structure of involuntary psychiatric holds in Institute of Psychiatry and Neurology in Warsaw, throughout the year. Our research interests included socio-demographic profiles of the patients, time of admissions (time of a day/night/ season), type of diagnoses at admission and suicide attempts preceding the admission. We also analysed the normative aspect of involuntary admissions, i.e. which Articles of the Polish Mental Health Act constituted the basis for these patients admission, and if the choice of articles was justifiable by a diagnosis of the mental disorder.
4.Symptom change trajectories during inpatient psychotherapy in routine care and their associations with long-term outcomes.
Melchior H1, Schulz H2, Kriston L3, Hergert A4, Hofreuter-Gätgens K5, Bergelt C6, Morfeld M7, Koch U8, Watzke B9. Psychiatry Res. 2016 Apr 30;238:228-235. doi: 10.1016/j.psychres.2016.02.046. Epub 2016 Feb 22.
This study examined symptom change trajectories during inpatient psychotherapy and the association of these changes with long-term outcomes. In an observational multicenter study, weekly measurements of symptom severity were performed during inpatient treatment and 6 months after discharge. The symptom severity was measured using the 18-item scale of the Hamburg Modules for the Assessment of Psychosocial Health. The sample included 576 inpatients (mean age: 43.9 years; 77.6% female; main diagnoses: depressive (57.2%), adjustment (15.8%), anxiety (7.4%), and eating disorders (7.2%); mean treatment duration: 42.0 days). With empirically and clinically informed growth mixture models four subgroups of symptom change were revealed: gradual response (71%), early response (9%), delayed response (5%), and nonresponse (11%). Particularly low educational level, non-employment and chronic disorders were associated with unfavorable symptom courses (non- and delayed response).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 525590-24-3 3-Amino-5-bromoindole

3-Amino-5-bromoindole
(CAS: 525590-24-3)

Chemical Structure

CAS 828-26-2 2,2,4,4,6,6-Hexamethyl-S-trithiane

Quick Inquiry

Verification code

Featured Items